| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | D D Richman | |
| P2860 | cites work | Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases | Q45853622 |
| Infection of Macaca nemestrina by human immunodeficiency virus type-1. | Q45865322 | ||
| Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy | Q45871865 | ||
| Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects | Q45873929 | ||
| Characterization of HIV isolates arising after prolonged zidovudine therapy | Q48192738 | ||
| Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy | Q54247387 | ||
| Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy | Q57832598 | ||
| Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy | Q62898209 | ||
| A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group | Q68158767 | ||
| State-of-the-art conference on azidothymidine therapy for early HIV infection | Q68537822 | ||
| Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine | Q28316118 | ||
| Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro | Q28316177 | ||
| [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1 | Q28318473 | ||
| Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs | Q28321397 | ||
| Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives | Q28323202 | ||
| Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor | Q28323582 | ||
| A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site | Q28323713 | ||
| Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase | Q28323740 | ||
| Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization | Q28323773 | ||
| BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine | Q28323825 | ||
| Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity | Q28323976 | ||
| Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors | Q28323994 | ||
| Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture | Q28324074 | ||
| Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase | Q28324076 | ||
| Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication | Q28324100 | ||
| Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction | Q28324151 | ||
| Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture | Q28324214 | ||
| In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine | Q28324338 | ||
| Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine | Q28326866 | ||
| Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy | Q28327738 | ||
| Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus | Q28333986 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) | Q28340342 | ||
| Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine | Q28342653 | ||
| Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine | Q28343184 | ||
| Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor | Q29547710 | ||
| Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera | Q33937159 | ||
| Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay | Q35250395 | ||
| HIV drug resistance | Q35706618 | ||
| Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay | Q35834444 | ||
| Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method | Q37511580 | ||
| Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication | Q37711871 | ||
| HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay | Q41646662 | ||
| Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes | Q41698277 | ||
| Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. | Q41745295 | ||
| HIV-1 sensitivity to zidovudine and clinical outcome in children | Q41996845 | ||
| 5-Aza-cytosine derivative chemotherapy in AIDS. | Q44846323 | ||
| Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus | Q45852268 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 1207-13 | |
| P577 | publication date | 1993-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents | |
| P478 | volume | 37 |
| Q28378859 | (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants [...] |
| Q33976617 | 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA |
| Q33690164 | A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer |
| Q35879410 | A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides |
| Q33782477 | A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine |
| Q28379499 | A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine |
| Q35132138 | A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques |
| Q34436519 | Advances in HIV treatment and treatment toxicities |
| Q41346811 | Analysis of inhibition of retroviral reverse transcriptase |
| Q35116619 | Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. |
| Q35104511 | Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase. |
| Q28369464 | Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro |
| Q40900124 | Antiretroviral agents. Current usage |
| Q28378892 | Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor |
| Q28379166 | Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease |
| Q33748925 | Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions |
| Q28368090 | Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease |
| Q37998496 | Candidate antibody-based therapeutics against HIV-1. |
| Q77654970 | Candidate antiretroviral agents for use in postexposure prophylaxis |
| Q28368832 | Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor |
| Q28369516 | Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor |
| Q28379084 | Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor |
| Q33814927 | Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay |
| Q43979142 | Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations |
| Q33782366 | Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutant |
| Q44479411 | Current antiretroviral therapy |
| Q36558109 | Current developments in HIV chemotherapy |
| Q41355296 | Cystamine Inhibits HIV Type 1 Replication in Cells of Monocyte/Macrophage and T Cell Lineages |
| Q41243158 | Development of nonnucleoside HIV reverse transcriptase inhibitors |
| Q35123292 | Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections |
| Q36672092 | Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals |
| Q45789645 | Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138→Arg and Tyr-188→His mutations |
| Q28378991 | Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication |
| Q24534187 | Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. |
| Q33640993 | HIV disease treatment in the era of HAART. |
| Q33732382 | HIV evolutionary genetics. |
| Q39876026 | Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group |
| Q35907177 | Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis |
| Q28378853 | Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors |
| Q35110966 | Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS |
| Q39989119 | In vitro evaluation of experimental agents for anti-HIV activity |
| Q33981972 | In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase |
| Q28367941 | In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease |
| Q41720036 | In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors. |
| Q28344355 | In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine |
| Q53842118 | Influence of protease inhibitor therapy on lipoprotein metabolism. |
| Q36536351 | Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group |
| Q36295462 | Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog |
| Q35132164 | Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene |
| Q37961181 | Mechanism of HIV antiretroviral drugs progress toward drug resistance |
| Q35122784 | Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription |
| Q40446517 | Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds |
| Q36278914 | Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity |
| Q24684152 | Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy |
| Q35126454 | Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine |
| Q43956445 | Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. |
| Q40992104 | New strategies for treating AIDS. |
| Q43503286 | Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents |
| Q92550561 | Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes |
| Q36525566 | Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. |
| Q37734538 | Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity |
| Q42186848 | Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine |
| Q45955820 | Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. |
| Q48406831 | P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors |
| Q40432241 | Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro. |
| Q35828466 | Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy |
| Q29620710 | Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry |
| Q44355582 | Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs |
| Q46661986 | Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations |
| Q40943840 | Recent development in the design of antiviral agents |
| Q40284727 | Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. |
| Q37574543 | Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. |
| Q28368381 | Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines |
| Q28367603 | Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720 |
| Q40531597 | Resistance to antivirals |
| Q41056531 | Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the com |
| Q53940587 | Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. |
| Q35129503 | Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals |
| Q41734947 | Saquinavir. Clinical pharmacology and efficacy |
| Q35123759 | Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine |
| Q35131540 | Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection |
| Q34181367 | Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. |
| Q27729431 | Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution |
| Q33757596 | Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase |
| Q35889066 | Subunit-specific mutagenesis of the cysteine 280 residue of the reverse transcriptase of human immunodeficiency virus type 1: effects on sensitivity to a specific inhibitor of the RNase H activity |
| Q28379196 | Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses |
| Q44124733 | Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors |
| Q71803216 | Testing anti–HIV drugs in the FIV model |
| Q44365601 | The existence of human immunodeficiency virus resistance to nucleoside-analog drugs has not been shown |
| Q77354777 | The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load |
| Q27732214 | The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design |
| Q35967419 | Therapy of HIV infection |
| Q40623726 | Treatment of HIV infection in infancy. |
| Q40931968 | Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences |
| Q41516241 | Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. |
| Q40884087 | Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice |
| Q45767976 | Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus |
| Q45765110 | Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment |
Search more.